As regulators examine the on-body injector used with isatuximab in multiple myeloma, Sikander Ailawadhi, MD, provides commentary on frequently asked questions. The European Medicines Agency’s ...

The U.S. Food and Drug Administration (FDA) on Wednesday delayed its decision on Sanofi SA’s SNY subcutaneous Sarclisa ...

ADAPT OCULUS is the first study to evaluate a targeted treatment for ocular MG, demonstrating that VYVGART significantly improves disease ...

Sikander Ailawadhi, MD, of the Mayo Clinic Florida in Jacksonville, discusses the clinical significance and primary outcomes ...

On-body injector delivery of subcutaneous teprotumumab achieves clinically meaningful proptosis reduction in phase 3 thyroid eye disease study.

Health and wellness influencers are hawking unapproved treatments on the gray market. The future of the F.D.A.—and the health of consumers—is at stake.

The four astronauts in the Artemis II mission are about 148,000 miles away from Earth, traveling at a velocity of 2,737 mph as of 11:18 a.m. ET April 9. The crew is roughly 7 days and 16 hours into ...

This report makes clear that technical prompt injections aren’t a theoretical problem, they’re a real and immediate risk.” — TJ Sayers, Senior Director of Threat Intelligence at CIS CLIFTON PARK, NY, ...

Roche Korea said Wednesday that the subcutaneous (SC) formulation of its multiple sclerosis (MS) treatment, Ocrevus (ocrelizumab), will be covered by the national health insurance starting Wednesday.

This study compares a novel, disc-preserving minimally invasive technique targeting intraforaminal inflammation—CT-guided transforaminal ozone injection (Group A)—with the conventional intradiscal ...